Trial Profile
Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Apr 2022
Price :
$35
*
At a glance
- Drugs Ergocalciferol (Primary) ; GAD65 vaccine (Diamyd) (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms DIAGNODE; DIAGNODE-1
- 01 May 2022 Results of DIAGNODE-1 and First in human DIAGNODE Extension study, published in the Acta Diabetologica
- 01 Sep 2020 Data from HLA analysis of this trial presented in a Diamyd Medical AB Media Release.
- 19 Feb 2020 Status changed from active, no longer recruiting to completed.